Prevention of Mother-to-child Transmission of HIV-1 Using a Rescue Intervention
Prevention of Mother-to-child Transmission of HIV-1 Using a Rescue Intervention
The second visit of the Expanded Programme of Immunization when the child is 2 months old
 (EPI-2) represents a unique opportunity to link the EPI and PMTCT programmes and to introduce
 preventive and therapeutic rescue interventions in order to: 1) Assess the efficacy of the
 PMTCT cascade up to 2 months postpartum; 2) Allow at least 80% of HIV-1-infected infants
 identified at the second EPI visit who were not involved in HIV care to initiate ARVs at the
 earliest, but no later than 2 months after confirmation of HIV diagnosis; 3) Reduce HIV-1
 transmission to less than 3% between 2 and 12 months among exposed children who completed the
 second EPI visit
In the vast majority of sub-Saharan African countries, all mothers attend an immunization
 (EPI) visit when their child is 6 to 8 weeks old (the first EPI visit for BCG and OPV0
 vaccination, takes place at childbirth).

 This study primarily aims at utilizing existing strategies to prevent postnatal HIV-1
 transmission through optimizing the use of lamivudine as pre-exposure prophylaxis (PrEP) for
 at risk children. For this purpose, the study will use recently marketed diagnostic point of
 care (POC) tests at the first level of care for maternal HIV-1 viral load and early infant
 diagnosis (EID). This POC early infant diagnosis will also allow optimizing treatment of
 HIV-infected infants by offering to all the benefits of an early ART initiation.

 The hypothesis is that the second visit for routine vaccination (Expanded Program of
 Immunization visit 2: EPI-2) represents a unique opportunity to link EPI and PMTCT programs
 and introduce rescue preventive and therapeutic interventions. The EPI visit will allow an
 opportunity to:

 1. Assess the efficacy of the PMTCT cascade.

 2. Identify HIV-1-infected children early and refer them for early initiation of treatment

 3. Provide their children with an antiretroviral drug that can protect them from HIV-1,
 irrespective of their mother's adherence to ART as part of the Phase III Randomized
 Controlled Trial.

 The Phase III RCT will be testing a rescue preventive intervention among HIV-1-uninfected
 children exposed to HIV-1 by their HIV-1-infected breastfeeding mothers against a control
 routine Option B+ implementation.

 Following a brief questionnaire and counselling on ART adherence and breastfeeding,
 participant mothers aged 15 years or older who meet eligibility criteria will be randomized
 to the control or intervention arms at a 1:1 ratio.

 The phase III Randomised Controlled Trial (RCT) testing a rescue preventive intervention
 among HIV-1-uninfected children exposed to HIV-1 by their HIV-1-infected breastfeeding
 mothers against a control routine Option B+ implementation.

 In the control arm, routine Option B+ national guidelines including HIV-1 plasmatic viral
 load testing will be adhered to as part of the clinics' usual practice. Visits will take
 place at 6-8 weeks, 6 and 12 months post-partum to collect samples from the mother for the
 analysis of viral load results at 12 months. In addition, at 6-8 weeks, 6 and 12 months
 post-partum, POC tests will be done for the diagnosis of HIV-1 in their infants (by HIV-1 DNA
 PCR) and results will be shared within 2 hours. Children infected with HIV-1 will be referred
 to the National Programme for confirmed diagnosis and immediate ART.

 The intervention arm aims at reducing the risk of HIV transmission for infants exposed to
 large amounts of HIV-1 through breastfeeding, which correlates with the maternal plasma viral
 load. At 6-8 weeks post-partum, a venous blood sample will be taken from the mothers to
 assess their viral load using a GenXpert® HIV RNA POC test. Concomitantly, a capillary blood
 sample will be taken from the child for the detection of HIV-1 (by HIV-1 DNA PCR). Children
 infected with HIV-1 will be referred to the National Programme for confirmed HIV diagnosis
 and immediate ART.

 For children that are not HIV-1 infected in the intervention arm, the results on the mother's
 viral load will guide the next steps:

 - Mothers with a detectable plasma viral load (≥ 1000 copies/mL) will receive reinforced
 counselling on ART adherence.

 In addition, their child will be initiated on PrEP, lamivudine syrup (7.5 mg twice daily if 2
 to 4 kg; 25 mg twice a day if weight <8 kg; and 50 mg twice a day if weight >8 kg). Mothers
 will come with their child to the study site every month (at M3, M4, M5, M7, M8, M9, M10 and
 M11) to collect drug supplies, safety follow-up, child's PrEP adherence adherence and
 counselling, mother's ART adherence and reporting. In Zambia, high risk HIV negative infants
 on a 12-week prophylactic regimen and are still taking ART at this visit, their first day of
 the study prophylaxis administration will take place at Month 3.

 - Mothers with an undetectable viral loads (<1000 copies/mL) will continue receiving ART
 adherence counselling. However, the children of these mothers will not be initiated on PrEP
 on the study at 6-8 weeks of age. However, because ART compliance declines rapidly over time
 within the first year of initiation, additional monitoring on the viral load of the mother
 and the diagnosis of the child will take place at 6 months: If the maternal plasmatic viral
 load is ≥ 1000 copies/mL, the child will be initiated on PrEP, lamivudine syrup (7.5 mg twice
 daily if 2 to 4 kg; 25 mg twice a day if weight <8 kg; and 50 mg twice a day if weight >8
 kg), until the baby is 12 months old or until the confirmed end of breastfeeding.
 Breastfeeding will be considered to be ceased if the mother confirms she is no longer
 breastfeeding for 2 consecutive monthly visits.

 Children infected with HIV-1 will be referred to the National Programme for confirmed
 diagnosis and immediate ART.
For HIV+ women who give consent, the measurement of their HIV-1 viral load and the
 detection of HIV-1 DNA in their children will be assessed.

 Inclusion Criteria:

 A mother/infant pair will be included in the Phase III trial if the infant:

 -  Is a singleton

 -  Is breastfed at 2 months and the mother intends to continue breastfeeding for at least
 4 months (until her child is 6 months old)

 -  Has a negative HIV-1 PCR POC test at 2 months of age

 -  Has a mother who:

 -  Is the accompanying person to visit 2 of the EPI

 -  Is 15 years of age or older (in Zambia) and 20 years of age or older (in Burkina Faso)
 or

 -  If between 15 and 19 years of age (inclusive) in Burkina Faso, and is accompanied by a
 referent adult of her choice representing her interests and the interests of the child
 (parent, family member or guardian, member of an association, etc.)

 -  Has been confirmed to be infected with HIV-1 (with or without HIV-2)

 -  Has signed the consent form to participate For the mother in Zambia, the consent must
 be signed by herself and a witness; For the mother in Burkina Faso, the consent must
 be signed by herself and a witness (if illiterate) and/or a referent adult (if under
 20 years of age in Burkina Faso).

 For the child in Zambia, the consent must be signed by the mother. For the child in Burkina
 Faso, the consent must be signed by the mother and/or a referent adult (if under 20 years
 of age in Burkina Faso. In Burkina Faso, both parents need to sign the consent unless the
 mother exercises sole parental authority or if obtaining the father's consent is likely to
 endanger the mother and her child. In Zambia, the mother exercises sole parental authority.

 Exclusion Criteria:

 A mother-child couple will not be included if the child:

 -  Has clinical symptoms or biological abnormalities of DAIDS classification 3 or 4 for
 adverse events on the day of inclusion

 -  Has a severe congenital malformation

 -  Has a known allergy to the study drug or its components

 -  Takes emtricitabine concomitantly

 -  Has a mother who:

 -  Lives outside the study area or intending to move from the area within the next 12
 months

 -  Is participating in another clinical trial